Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22ecc2f4ee7cfc3

Jump to content

Exelgyn

Add links
From Wikipedia, the free encyclopedia
Exelgyn
IndustryPharmaceutical
HeadquartersParis, France
Area served
Worldwide
Productsmifepristone, misoprostol.
Websitehttps://exelgyn.com/

Exelgyn is a French pharmaceutical company which makes and distributes the medical abortion drugs mifepristone (marketed as Mifegyne) and misoprostol.

History

[edit]

Mifepristone was discovered in France in 1980 by scientists at Roussel-Uclaf, in a pharmaceutical program aimed at the identifying agents acting as antagonists of glucocorticoids; with the observation that it also displayed anti-progestational properties, it was developed as an abortifacient, and was approved for sale in the French market in 1987.[1]

In December 1996, pharma business news reported Hoechst AG's intent to buy the remaining share of Roussel-Uclaf stock that it did not yet own (43.5%).[2][3][full citation needed][4][full citation needed]

Exelgyn is a firm founded in 1997, and as of May 2026, it was defined by a private partnership structure known in France as an Société par actions simplifiée (SAS).[5][6][7] It was designed as a single-product company immune to antiabortion boycotts.[citation needed] Its CEO was former Roussel-Uclaf CEO Édouard Sakiz.[2]

Hoechst announced cessation of its manufacture of the mifepristone in April 1997, and transferred all rights for its manufacture and sales outside of the United States to Exelgyn.[8][9][10][11][full citation needed][12][full citation needed]

In 1999, Exelgyn won approval to market Mifegyne in 11 additional countries.[citation needed] As of 2024, Exelgyn was reporting that it was distributing mifepristone to 40 countries,[13][date missing] although its manufacture and distribution in the U.S. market was by Danco Laboratories and GenBioPro.[citation needed]

References

[edit]
  1. ↑ Corey E.J.; Czakó, B. & Kürti, L. (2012). "Mifepristone". Molecules and Medicine. New York, NY: John Wiley & Sons. ISBN 978-1-118-36173-3. Archived from the original on 8 September 2017. Retrieved 2026-05-04.{{cite book}}: CS1 maint: multiple names: authors list (link)
  2. 1 2 Bloomberg Staff (1996-12-11). "Hoechst to Buy Rest of Roussel". The New York Times. Bloomberg News. p. D4. Archived from the original on 25 June 2016.
  3. ↑ Moore, S.D.; Kamm, T. & Fleming, C. (11 December 1996). "Hoechst to Seek Rest of Roussel-Uclaf; Expected $3.04 Billion Offer Would Add to the Wave of Drug-Sector Linkups". The Wall Street Journal. p. A3.{{cite news}}: CS1 maint: multiple names: authors list (link)[full citation needed]
  4. ↑ Marshall, M. (11 December 1996). "Hoechst Offers to Pay $3.6 Billion for Rest of Roussel". The Wall Street Journal. p. A8.[full citation needed]
  5. ↑ North Data Staff (2026-05-04). "Exelgyn SAS, Paris, France". North Data (NorthData.com). Retrieved 2026-05-04.
  6. ↑ Stripe.com Staff (August 2, 2024). "What to Know About the Société par Actions Simplifiée (SAS) in France". Stripe.com. Retrieved 2026-05-04.
  7. ↑ MPAA Staff (2026-05-04). "Société par Actions Aimplifiée (SAS): Ce Qu'il Faut Savoir". Ministry of Public Action and Accounts (MPAA; Economie.Gouv.Fr). Paris, France: Government of France. Retrieved 2026-05-04.
  8. ↑ Bloomberg Staff (9 April 1997). "Pill for Abortion Ends Production". The New York Times. Bloomberg News. p. D2. Archived from the original on 25 June 2016.
  9. ↑ Jouzaitis, C. (9 April 1997). "Abortion Pill Maker Bows to Boycott Heat; German Firm Gives Up RU-486 Patent; Little Impact Likely in U.S." Chicago Tribune. p. 4. Archived from the original on 18 February 2013.
  10. ↑ Dorozynski, A. (19 April 1997). "Boycott Threat Forces French Company to Abandon RU486". BMJ. 314 (7088): 1150. doi:10.1136/bmj.314.7088.1145m. PMC 2126515. PMID 9146386.
  11. ↑ Lavin, D. (9 April 1997). "Hoechst Will Stop Making Abortion Pill". The Wall Street Journal. p. A3.[full citation needed]
  12. ↑ RFN Staff (18 April 1997). "Roussel-Uclaf to Transfer RU 486 Rights". Reproductive Freedom News (RFN). 6 (7): 8. PMID 12292550.[full citation needed]
  13. ↑ "Our global presence – Exelgyn". Retrieved 2026-05-04.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Exelgyn&oldid=1359433943"